Bertek Submits NDA For Nebivolol; Beta Blocker Would Be Firm’s Third Branded Antihypertensive
This article was originally published in The Pink Sheet Daily
Executive Summary
The Mylan subsidiary claims patent protection into 2020 for nebivolol, a cardioselective beta blocker with vasodilating properties licensed from Janssen.